确定控制腹水同时减少TIPS术后肝性脑病的最佳门静脉压力降幅:一项多中心研究
该多中心研究纳入3个欧洲中心2000至2023年间接受TIPS植入的729例患者,采用竞争风险随机生存森林等分析,确定门静脉压力梯度降幅60%-80%时腹水相关失代偿显著减少且显性肝性脑病发生率未增加,该范围在验证队列中得到确认。
要点
- 门静脉压力梯度降幅60%-80%时,腹水相关失代偿显著减少(sHR 0.7),显性肝性脑病发生率未显著增加(sHR 0.92)。
- 验证队列确认该降幅范围:腹水相关失代偿sHR 0.66,显性肝性脑病sHR 0.89。
- 作者认为门静脉压力梯度降幅60%-80%可作为有效的降压目标。
核心结论
- 门静脉压力梯度降幅60%-80%可显著减少腹水相关失代偿且不增加显性肝性脑病风险,该范围可作为有效的降压目标。
研究设计与样本
- 多中心研究,筛选3个欧洲中心(汉诺威、维也纳、汉堡)2000至2023年间接受TIPS植入的1509例患者,最终分析729例,队列分为60%推导队列(438例)和40%验证队列(291例)。
主要发现
- 推导队列中,门静脉压力梯度降幅60%-80%的患者腹水相关失代偿显著减少(sHR 0.7 [0.52-0.96]),显性肝性脑病发生率相似(sHR 0.92 [0.67-1.27])。
- 验证队列确认该范围:腹水相关失代偿sHR 0.66 [0.46-0.96],显性肝性脑病sHR 0.89 [0.61-1.32]。
关键数值与推荐
- 最佳门静脉压力梯度降幅为60%-80%,由最大选择Gray统计量和随机生存森林的部分依赖图确定。
临床怎么用
- 作者认为门静脉压力梯度降幅60%-80%可作为有效的降压目标。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Clinically significant portal hypertension in patients with liver cirrhosis can lead to refractory ascites. A TIPS treats clinically significant portal hypertension but may cause overt hepatic encephalopathy (oHE). Our aim was to determine the optimal reduction of the portal pressure gradient (PPG) through TIPS to control ascites without raising oHE risk. APPROACH AND RESULTS: This multicenter study screened 1509 patients from 3 European centers (Hannover, Vienna, and Hamburg) undergoing TIPS implantation between 2000 and 2023. Patients with TIPS indications other than refractory ascites/hepatic hydrothorax, vascular liver disease, HCC, or insufficient PPG data were excluded. PPG was measured before and after TIPS insertion. Outcome data were assessed up to 1 year after TIPS insertion. Analyses were conducted utilizing a modern machine learning model, namely a competing-risk random survival forest, partial dependence plots, and competing risk analyses with liver transplantation/death as competitors. The cohort was divided into a 60% derivation and 40% validation cohort. Overall, 729 patients (median MELD: 13 [IQR 10-16], 66% male, 23% oHE before TIPS) were analyzed. The derivation cohort comprised 438 patients, and the validation cohort comprised 291 patients. The optimal PPG reduction, determined by maximally selected Gray statistic and PDP of the random survival forest, was 60%-80%. In this range, patients showed significantly fewer hepatic decompensations due to ascites (HDA) (subdistribution hazard ratio [sHR]: 0.7 [0.52-0.96]) with similar oHE incidences (sHR: 0.92 [0.67-1.27]). The PPG range was confirmed in the validation cohort (HDA: sHR: 0.66 [0.46-0.96]; oHE: sHR: 0.89 [0.61-1.32]). CONCLUSIONS: A targeted PPG reduction of 60%-80% showed significantly reduced HDA without increased oHE risk. Therefore, PPG reduction within this range could be a valid reduction target.
引用
- Kabelitz MA, Hartl L, Schaub G, et al. Identification of optimal portal pressure decrease to control ascites while minimizing HE after TIPS: A multicenter study. Hepatology. 2025. PMID: 39773850. doi:10.1097/HEP.0000000000001219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。